Cephalon, Inc., received approval from the FDA for Treanda for Injection for the treatment of patients with indolent B-cell non-Hodgkin’s lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. In March, Treanda received approval for the treatment of patients with chronic lymphocytic leukemia, the most common form of leukemia in the U.S.      Indolent NHL, a subset of non-Hodgkin’s lymphoma, is a slow-growing ...